ArticleJournal of virology2004
Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 102 citations in OpenAlex.
- In Silico and in vitro evaluation of Cucurbitaceae seed lectins as promising prophylactic and therapeutic agents against SARS-CoV-2.Glycoconjugate journal · 2025Article
- Lectins Are the Sparkle of Hope for Combating Coronaviruses and the Global COVID-19.Advanced pharmaceutical bulletin · 2022Review
- 35 years in plant lectin research: a journey from basic science to applications in agriculture and medicine.Glycoconjugate journal · 2022Article
- Legume Lectins with Different Specificities as Potential Glycan Probes for Pathogenic Enveloped Viruses.Cells · 2022Review
- Overview of the Structure⁻Function Relationships of Mannose-Specific Lectins from Plants, Algae and Fungi.International journal of molecular sciences · 2019Review
- Human Cervical Epithelial Cells Release Antiviral Factors and Inhibit HIV Replication in Macrophages.Journal of innate immunity · 2019Article
- Antiviral lectins: Selective inhibitors of viral entry.Antiviral research · 2017Review
- HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.Expert opinion on therapeutic targets · 2015Review
- Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins.Molecules (Basel, Switzerland) · 2015Article
- Ebola virus (EBOV) infection: Therapeutic strategies.Biochemical pharmacology · 2015Review
- NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles.The Journal of antimicrobial chemotherapy · 2015Article
- The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents.Retrovirology · 2014Article
- Bitter-sweet symphony: glycan-lectin interactions in virus biology.FEMS microbiology reviews · 2014Review
- Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA.Molecular pharmaceutics · 2013Article
- Article
- Potential of carbohydrate-binding agents as therapeutics against enveloped viruses.Medicinal research reviews · 2012Review
- Molecular architecture and therapeutic potential of lectin mimics.Advances in carbohydrate chemistry and biochemistry · 2012Review
- Purification and characterization of a novel plant lectin from Pinellia ternata with antineoplastic activity.SpringerPlus · 2012Article
- The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry.The Journal of biological chemistry · 2011Article
- Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry.Molecular pharmaceutics · 2011Article
Corrections and comments
- Erratum issuedBöhlmstedt, Anders [corrected to Bölmstedt, Anders]
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mannose-specific plant lectins from the Amaryllidaceae family (e.g., Hippeastrum sp. hybrid and Galanthus nivalis) inhibit human immunodeficiency virus (HIV) infection of human lymphocytic cells in the higher nanogram per milliliter range and suppress syncytium formation between persistently HIV type 1 (HIV-1)-infected cells and uninfected CD4(+) T cells. These lectins inhibit virus entry. When exposed to escalating concentrations of G. nivalis and Hippeastrum sp. hybrid agglutinin, a variety of HIV-1(III(B)) strains were isolated after 20 to 40 subcultivations which showed a decreased sensitivity to the plant lectins. Several amino acid changes in the envelope glycoprotein gp120, but not in gp41, of the mutant virus isolates were observed. The vast majority of the amino acid changes occurred at the N glycosylation sites and at the S or T residues that are part of the N glycosylation motif. The degree of resistance to the plant lectins was invariably correlated with an increasing number of mutated glycosylation sites in gp120. The nature of these mutations was entirely different from that of mutations that are known to appear in HIV-1 gp120 under the pressure of other viral entry inhibitors such as dextran sulfate, bicyclams (i.e., AMD3100), and chicoric acid, which also explains the lack of cross-resistance of plant lectin-resistant viruses to any other HIV inhibitor including T-20 and the blue-green algae (cyanobacteria)-derived mannose-specific cyanovirin. The plant lectins represent a well-defined class of anti-HIV (microbicidal) drugs with a novel HIV drug resistance profile different from those of other existing anti-HIV drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.